Cephalon/Lundbeck Discontinue Phase II/III Parkinson’s Agent
This article was originally published in The Pink Sheet Daily
The compound CEP-1347 failed to demonstrate efficacy over placebo, a data monitoring committee determined. The mixed-lineage oral kinase apoptosis inhibitor was thought to prevent neuronal apoptosis. Novartis also discontinued development of a similar Phase II agent.
You may also be interested in...
Surge of interest prompts US FDA to consider how to adjust feedback, including potentially creating a separate team to answer more basic questions.
When the closest you can get to US FDA staff is Webex, the meeting minutes and interactions with the review team project manager take on increased importance, consultants suggest during an Informa-sponsored webinar.
Amid the COVID-19 pandemic, Richard Pazdur doesn’t want the cancer patient forgotten. His solution: keep churning out approvals.